Study detail
RecruitingPhase 3
A Phase 3, Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of BMS-986353, CD19-targeted NEX-T CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis (Breakfree-SSc)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Summary
The purpose of this study is to compare the efficacy and safety of BMS-986353 versus standard of care in participants with active Systemic Sclerosis
Description
Participants in Arm B may receive BMS-986353 following confirmation of progression on standard of care.
Eligibility
- Age range
- 16+ years
- Sex
- All
- Healthy volunteers
- No